CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 31 enrolled
Drug / intervention
florbetapir F 18drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00857532
NCT00857532Phase 2Completed
CompareCT.gov

A Phase 2 Trial of Florbetapir F18 PET Imaging of β-amyloid in Parkinson's Disease Patients With Cognitive Impairment

Avid Radiopharmaceuticals·interventional·Posted Mar 6, 2009·Updated Mar 11, 2013

In Brief

A Phase 2 clinical trial evaluating florbetapir F 18 for Parkinson's Disease. Completed, enrolled 31 participants across 1 site.

Detailed Summary

The primary aim of this study is to compare regional amyloid burden in Parkinson's disease (PD) to normal control subjects. We hypothesize that there will be significant differences in overall amyloid burden in PD patients compared to age-matched normal controls.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson's Disease
CountriesUnited States
CollaboratorsNational Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS)

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedMar 6, 2009
Enrollment StartJan 1, 2009
Primary CompletionNov 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 17.3 years ago

Interventions

florbetapir F 18drug

10 millicurie (mCi) (370 MBq) florbetapir F 18 Injection